Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of Retroviruses and Opportunistic Infections (CROI) 2025 on its ensitrelvir.
This included new data from its global, double-blind, randomized, placebo-controlled Phase III study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post-Exposure Prophylaxis (SCORPIO-PEP) assessing ensitrelviras oral post-exposure prophylaxis.
Shionogi stated that SCORPIO-PEP is the first and only Phase III study of a COVID-19 oral antiviral as a post-exposure prophylaxis to meet the primary endpoint of preventing COVID-19.*
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze